Journal of Thrombosis and Thrombolysis

Article	Citations
Post-thrombolytic coagulopathy and complications in patients with pulmonary embolism treated with fixed-dose systemic alteplase	48
Meta-analysis of restrictive versus liberal blood transfusion among patients with coronary artery disease	45
The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China	44
Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation	33
ICODE: the international COVID-19 thrombosis biomarkers colloquium—novel soluble biomarkers: circulating cell-free nucleic acids and other molecules	33
Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement	32
Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia	28
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity	28
Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid	27
Endothelial progenitor cells overexpressing platelet derived growth factor-D facilitate deep vein thrombosis resolution	24
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population	24
Prevalence and consequences of empiric anticoagulation for venous thromboembolism in patients hospitalized for COVID-19: a cautionary tale	23
Safety and efficacy of catheter-directed therapy versus anticoagulation alone in a higher-risk acute pulmonary embolism population	22
Incidence of thrombotic complications in COVID-19	22
Different patterns of white matter lesions among patent foramen ovale, atherosclerotic cerebral small vessel disease and cerebral venous thrombosis	20
The clot thickens—enhanced integration of stroke and thrombosis training	20
Conservative treatment vs thrombus removal for Iliofemoral vein thrombosis in patients with congenital abnormalities of the inferior vena cava: a case report and systematic review of the literature	20
Inhibitory effects of amniotic fluid on the activated protein C anticoagulation system in maternal plasma	19
Barriers and motivators to national board certification as a certified anticoagulation care provider	19
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection	18
Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial	17
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis	17
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	17
Initial assessment of α-synuclein structure in platelets	17
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	16

Uncertainties about platelet function and genetic testing for guiding dual antiplatelet therapy in percutaneous coronary intervention	16
Evaluating the safety and efficacy of intravenous thrombolysis for acute ischemic stroke patients with a history of intracerebral hemorrhage: a systematic review and meta-analysis	16
Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson’s syndrome	15
Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation	15
Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria	15
Thrombectomy for ischemic stroke with large vessel occlusion and concomitant subarachnoid hemorrhage	14
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction	14
Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series	14
Prescribing of anticoagulation for atrial fibrillation in primary care	14
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	14
Second wave of the COVID-19 pandemic: D-dimer levels are not so high anymore	13
Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients	13
Roles of factor Xa beyond coagulation	13
Correction to: Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia?	13
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography	13
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)	13
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database	12
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	12
Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score	12
Global coagulation assays in hypercoagulable states	12
Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction	11
COVID 19 infection associated with thrombotic thrombocytopenic purpura	11
Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status	11
Risk of recurrent venous thromboembolism and bleeding in patients with interstitial lung disease: a cohort study	11
Guest editors’ introduction	11
International COVID-19 biomarkers colloquium	11
REPLY to “Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	11
Recurrent hematuria and painful necrotic purpura induced by acquired Protein S deficiency associated with monoclonal immunoglobulin	11
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis	11
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?	11
Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics	11
Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study	11
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors	10
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate	10
Sickle cell disease related chronic thromboembolic pulmonary hypertension: challenging clinical scenario	10
Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 d	10
Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation	9
Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma	9
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells	9
Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation	9
Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment	9
Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall	9
Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention	9
Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes	9
Increased incidence of massive hemorrhage at uncommon sites after initiation of systemic anticoagulation in critically ill patients with coronavirus disease 2019 (COVID-19) infection	9
Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity	9
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	8
Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event	8
Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study	8
Contemporary use of ventilation-perfusion imaging for pulmonary embolism diagnosis	8

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians	8
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series	8
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid	8
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	8
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19	8
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	8
Utilization of D-dimer assay, CT angiography, and the incidence of pulmonary embolism in the hospital district of Helsinki and Uusimaa (2011–2017)	8
Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center	8
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	7
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry	7
Confirmation of the utility of the Wells’ Score for pulmonary embolism in patients with sickle cell disease	7
Analysis of changes in the expression pattern of miR-326 and miR-145 during storage of platelet concentrate in blood bank condition and its relationship with some markers of platelet quality	7
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients	7
Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation pati	7
COVID-19 risk index (CRI): a simple and validated emergency department risk score that predicts mortality and the need for mechanical ventilation	7
Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012)	7
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study	7
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics	7
Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway	7
Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients	7
Management of bone marrow biopsy related bleeding risks: a retrospective observational study	7
Incremental cost of venous thromboembolism in trauma patients with contraindications to prophylactic anticoagulation: a prospective economic study	7
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	7
Immature platelets in patients with Covid-19: association with disease severity	7
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage	7
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia	7
Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy	6
Hospitalization for venous thromboembolic disease management: a 10 years Registry in Buenos Aires, Argentina	6
Efficacy of interatrial shunt devices: an opening window to acute pulmonary hypertensive crisis and chronic pulmonary arterial hypertension	6
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis	6
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists	6
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE tr	6
Transient endothelial injury and release of lupus anticoagulant in COVID-19	6
Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI	6
Vitamin D levels and C-reactive protein/albumin ratio in pregnant women with cerebral venous sinus thrombosis	6
Screening for venous thromboembolism in patients with COVID-19	6
Acute limb ischemia in a patient with Covid-19 pneumonia: a case report	6
Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody	5
The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF	5
U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients	5
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis	5
Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: epidemiology, outcomes, and diagnostic challenges	5
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients	5
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	5
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals	5
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer	5
Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves	5
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic	5
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA	5
Overexpression of miR-1298 attenuates myocardial ischemia–reperfusion injury by targeting PP2A	5
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies	5
Safety of intravenous thrombolysis in stroke of unknown time of onset: A systematic review and meta-analysis	5
Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia	5
A rare case of non-traumatic spinal epidural hematoma in lumbar region associated with apixaban therapy	5
Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism	5
Inpatient Management of Pulmonary Embolism: Clinical Characteristics and Mortality in a High-Volume Tertiary Care Center	5
A comprehensive review of vascular complications in COVID-19	5
Association of acidosis with coagulopathy and transfusion requirements in liver transplantation	5
Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke	5
Efficacy of a hypolipid diet in patients with primary antiphospholipid syndrome with dyslipidemia: a prospective study	5
Development and validation of a prediction model of catheter-related thrombosis in patients with cancer undergoing chemotherapy based on ultrasonography results and clinical information	5
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	5
Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic	5
Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome	4
MicroRNA-29b reduces myocardial ischemia–reperfusion injury in rats via down-regulating PTEN and activating the Akt/eNOS signaling pathway	4
Efficacy and safety of pre-operative insertion of inferior vena cava filter in patients undergoing bariatric surgery: a systematic review	4
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study	4
Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens	4
Ruthenium chloride inhibits the anticoagulant activity of the phospholipase A2-dependent neurotoxin of Mojave rattlesnake Type A venom	4
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality	4
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	4
High levels of von Willebrand factor with reduced specific activities in hospitalized patients with or without COVID-19	4
Nitric oxide acute kidney injury (NO-AKI) pilot trial	4
Impact of the pandemic of COVID-19 on emergency attendance for stroke and acute myocardial infarction in Beijing, China	4
Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross‐sectional study	4
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	4
Biomarkers associated with coronary high-risk plaques	4
Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice	4
Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes	4
Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection	4

Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study—Reply to comment from Muzaffar et al.	4
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry	4
In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016–2018	4
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison	4
Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome	4
Favourable collaterals according to the Careggi Collateral Score grading system in patients treated with thrombectomy for stroke with middle cerebral artery occlusion	4
Practice patterns surrounding referral to a specialty venous thromboembolism (VTE) clinic: a retrospective review	4
Study on the activity of recombinant mutant tissue-type plasminogen activator fused with the C-terminal fragment of hirudin	4
Tissue factor: a neglected role in cancer biology	4
Primary pulmonary artery sarcoma versus pulmonary thromboembolism: a multimodal imaging comparison	4
Answer to “REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	4
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19	4
Stroke risk factors and outcomes among hospitalized women with atrial fibrillation	4